Soretolide: Laboratoires Biocodex

M. O. Fatope*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)

Abstract

Laboratoires Biocodex is developing soretolide (D-2916) as a potential treatment for epilepsy. It is currently in phase II trials. In animal models, soretolide shows an anticonvulsant profile similar to carbamazepine, being active in the maximal electroshock test and poorly active against pentylenetetrazole-induced seizures. The company is currently discussing future development plans for this drug.

Original languageEnglish
Pages (from-to)824-827
Number of pages4
JournalCurrent Opinion in Investigational Drugs
Volume2
Issue number6
Publication statusPublished - 2001

ASJC Scopus subject areas

  • Pharmacology

Fingerprint Dive into the research topics of 'Soretolide: Laboratoires Biocodex'. Together they form a unique fingerprint.

Cite this